Vivimed Labs Limited
VIVIMEDLAB · NSE · Healthcare
StocksWizard rates Vivimed Labs Limited a Strong Sell, scoring 6/100 on our blended model. At ₹5.92 there isn't enough clean financial data for a confident fair-value estimate, so we hold back an intrinsic verdict here. Financial health scores 0/100 (grade F), with a Piotroski F-score of 2/9. It clears 0 of 6 investability checks, with durability 0, valuation 15 and momentum 5 on our 0–100 scales.
These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
Piotroski F-score 2/9 — quality of earnings & balance sheet.
Investability checklist
- –ROE above 15%
- –Low debt (D/E < 0.5)
- ✕Positive free cash flow
- ✕Revenue growth > 10%-56%
- –Earnings growing
- ✕Net margin ≥ 10%-39.5%
- –Current ratio > 1.5
- –Below our fair value
- –Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- –Altman Z in safe zone
- ✕Piotroski ≥ 72/9
1-year price
EOD · 2026-06-19Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Weaknesses
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (2/9).
Opportunities
- •Well off its 52-week high — possible mean-reversion.
Threats
- •Rich valuation versus sector peers.
About Vivimed Labs Limited
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pa
More in Healthcare
All stocksOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.